-
Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)
Tuesday, July 2, 2013 - 8:58am | 628Read More...Things are starting to heat up in the already hot pharmaceutical sector – especially as it relates to mergers and acquisitions. Only days after Onyx Pharmaceuticals (NASDAQ: ONXX) said it rejected an $8.7 billion buyout offer from Amgen (NASDAQ: AMGN), according to Reuters, the company has...
-
Onyx Rejects Amgen Bid - But Open to Other Offers (ONXX, AMGN)
Monday, July 1, 2013 - 9:30am | 541Read More...Onyx Pharmaceuticals (NASDAQ: ONXX), Friday, turned down an offer from Amgen (NASDAQ: AMGN) to acquire all of Onyx's outstanding shares for $120 per share in cash, according to The Wall Street Journal. While Onyx said the proposed offer from Amgen significantly undervalued Onyx, the company did...
-
Pfizer's New Program May Help Men Get Up the Courage to Treat Erectile Dysfunction
Monday, May 6, 2013 - 2:56pm | 588Read More...In a move designed to take bashfulness out of the erectile dysfunction equation, drugmaker Pfizer (NYSE: PFE) told The Associated Press that it will begin selling its popular pill, Viagra, directly to patients on its website. A prescription will still be needed, but coming face to face with a...
-
Likely Winners and Losers in Obama's 2014 Budget
Thursday, April 11, 2013 - 10:21am | 646Read More...President Barack Obama’s proposed $3.8 trillion budget is designed to cut the deficit by $600 billion over 10 years, after factoring in the negation of cuts already enacted under the sequester according to The Associated Press. Depending on the framework of the final budget, some businesses...
-
Citi Comments On Pfizer In A 1Q11 10-Q Review (PFE)
Monday, May 16, 2011 - 7:46am | 106Read More...In a recent report, Citi has reiterated a $23.00 price target on Pfizer (NYSE: PFE) and maintained a Hold rating on the company in a 1Q11 10-Q Review. Citi has also noted that there needs to be business development in the primary care segment to quell decreasing profitability. In the report, Citi...
